Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
COVID-19 caused by SARS-CoV-2 virus has affected the lives of millions of individuals
globally and also severely strained the medical community. Pre-symptomatic and asymptomatic
SARS-CoV-2 positive individuals far outnumber the symptomatic ones or those with severe
disease. The transmission potential of SARS CoV-2 is potentially greater than earlier viral
outbreaks of SARS-CoV and MERS-CoV.Routine measures of social distancing, personal hand
hygiene and limited outdoor contact activities have shown benefits to limit corona virus
infection. However, the role of vitamin D in SARS-CoV-2 infection is sparingly explored
despite the knowledge of an immunomodulatory role and protective effect of vitamin D against
viral infections. Meta-analysis of five clinical trials of vitamin D supplementation found
that those receiving vitamin D supplementation had fewer respiratory tract infections (odds
ratio = 0.58 (95%CI, 0.42 - 0.81).Any immune-modulatory effect of vitamin D is likely to be
observed at levels which are considered higher than that required for normal bone metabolism.
Phase:
Phase 4
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research